Thank you, Robin. Good morning, and thank you for joining us. I'm pleased with Aflac's overall financial and operational performance in the second quarter. I believe we've established a solid foundation toward achieving our annual operating earnings growth and capital strength objectives. With half the year behind us, we believe we have substantially completed our proactive investment de-risking program from a realized investment loss perspective. I'll give you more details later, but first, I'll begin with a review of our operations in Japan and the United States. Aflac Japan generated strong financial results for both the second quarter and the first 6 months of the year. Revenue growth rose 3.7% for both the quarter and the first 6 months. In addition, our pretax margin continued to expand, resulting in solid earnings growth for the quarter and for the 6 months. We are particularly pleased with the continued sales momentum in the quarter. New annualized premium sales in yen exceeded our expectations and rose 6.6% to JPY 36.1 billion for the quarter, which was a record for the second quarter production. For the first half of the year, total new sales rose 9.4%. These results are even more remarkable when you consider that Aflac Japan overcame challenges resulting from the most destructive and devastating natural disaster in Japan's history. With the expanding bank channel in mind, Aflac Japan has developed innovative products that align well with the product needs of banks. Bank sales continued a strong growth trend with sales of JPY 7.6 billion, which represents an increase of 95.6% over the second quarter of 2010. Sales through banks accounted for more than 21% of the total sales for the second quarter. I'll mention how we believe more banks, mega banks, in particular would step up their efforts in selling Aflac products, and that's exactly what we've been seeing. At the end of June, Aflac Japan was represented by 367 banks or more than 90% of the total number of banks in Japan. While many banks have agreed to sell our products, turning that agreement from ink on paper into sales does not happen overnight, especially with more than 20,000 branches representing 367 banks. It will take some time to facilitate training at all these locations. But we're continuing to see sales steadily improving at many of these bank branches as training continues and the banks expand their offering of Aflac's products. In many of these banks, sales representatives have gained experience at selling our products, and their confidence level in sales ability has also grown. WAYS, which is especially popular with banks, was again a key driver to the growth in the second quarter. You will recall that WAYS in our unique hybrid whole life product that can be converted to a fixed annuity, medical coverage or nursing care benefits when the policy holder reaches a predetermined age. WAYS has been a phenomenal sales growth story, and in the second quarter generated an increase of 190.7% compared with the second quarter of 2010. Consumers find WAYS attractive because of its guaranteed principle and future flexibility of its benefit options. Banks like to sell this product because of the high premium and attractive commissions. And Aflac's profit margin on WAYS is more than double the profit margin for child endowment. On top of that, the profit margin is significantly enhanced even further when the policy holders elect to pay all their premiums upfront through the discounted advanced premium option. Importantly, 90% of the company's customers at the banks choose this type of payment. As our banking channel becomes a greater contributor to our top line growth, we expect sales of the innovative and flexible products to grow significantly in 2011. With respect to child endowment product, as we expected, sales decline posting a decrease of 1.4% for the quarter. Furthermore, we have already seen sales of child endowment decline so far in July, and we expect sales of child endowment to continue to decline significantly for the remainder of the year. First and foremost, as we told you, we are shifting our focus from selling child endowment towards selling WAYS and our new cancer product, DAYS. Second, having sold the child endowment product for 2 years now, we've already cycled through major first pass at selling our child endowment product to the eligible target of families in young people. At this range [ph], the remaining growth will primarily come from newborns, bearing in mind that Japan's birthrate is low. And finally, the government's towns and cities [ph] that initially helped fuel demand for this product is being re-evaluated for possible reduction or elimination. As such, we expect child endowment sales to diminish. The foundation of the product portfolio has been and continues to be our cancer and medical products. Importantly, we maintained our position as the #1 seller of cancer and medical products in Japan, which confirms the continued popularity and demand for our innovative policies. Following the March 2011 introduction of DAYS, cancer insurance sales increased 12.4% for the quarter. The enhancements to this new base policy speaks to the changing landscape in cancer treatments, as well as our commitment to remaining the #1 provider of cancer insurance in Japan. Sales of cancer insurance accounted for 24.4% of the total sales. I don't think when the earthquake and the tsunami struck, followed by the nuclear issue, that anyone would have believed Aflac Japan sales would be up 6.6% for the second quarter and 9.4% for the first 6 months. This is a remarkable achievement and I am extremely proud of Aflac Japan. As I've told you, following 2 years of strong sales results, the same comparisons get tougher as the year goes on, especially in the fourth quarter of 2011. However, with better-than-expected sales results in the first and second quarter, we are upwardly revising Aflac sales target to achieve flat to up 5% sales increase. Now let me turn to our U.S. operation. We are very pleased with Aflac U.S. performance from both a sales and a financial perspective. Aflac U.S. generated a 5.9% increase in new annualized premium for the second quarter, and a 6.1% sales increase for the first 6 months. These results have benefited greatly from the addition of group products to the Aflac U.S. product portfolio. We are especially encouraged to see that the production from veteran agents continued to increase. Additionally, we continue to see crossover where Aflac's career agents embraced group products. To me, it boils down to giving our customers the choice between group and individual products. When it comes to selling group versus individual products, I've told our entire U.S. sales force many times that I'm product neutral. I don't care whether they sell group or individual products, but I do want both products to be offered at the work site to employers with more than 100 workers. That's because we don't offer the group product upfront, you can bet someone else will. I truly believe that if the employer wants group products and hears Aflac offers them, they'll choose Aflac over the competition. And that is proving to be true. As you'll recall from both group and individual policies, we started driving sales earlier this year through specific product pushes called Smart Launches. Through these coordinated sales and marketing efforts, we look at the existing accounts, particularly those accounts most likely that need a particular product. We then align our field force resources strategically and efficiently target these accounts. Our first Smart Launch was held in the first quarter and focused on promoting dental product. Building on the success of that effort, dental sales increased 44.1% over the second quarter of 2010. Our second Smart Launch promotes the critical care recovery product, which was previously called a specified health event product. Because this Smart Launch begins in the middle of the second quarter, it's too early to quantify its full impact, but we're excited about how our sales is embracing both the product itself and the Smart Launch. On the distribution side, our strategy, we've said many times before that today's recruits are tomorrow's sales. Field force recruiting continues to benefit from a targeted national advertising campaign, generating a 10.2% increase of recruits for the second quarter and 11.9% for the first half of the year. We believe improved Aflac's U.S. sales, not only reflect our intense focus on supporting our field with enhanced products, including group products, but also reflects better resources and training that helps our sales force better approach selling in the current environment. We will continue to help our entire distribution network, new and veteran agents, as well as brokers, with ways they can improve their performance, because they are essential part of our strategy and our success. We continue to believe the U.S. is a vast and accessible market for our products, and we are building our business with that potential in mind. We also believe the expectations at Aflac U.S. sales growth for 2011 will be flat to up 5% is reasonable. Our sales and recruiting trends are working in our favor, and I feel even better today than I did at the Analyst Meeting in May, and I'm optimistic that these trends will continue. It's clear that the addition of the group product platform and our growing broker initiative only served to enhance our ability to leverage Aflac's brand to reach more customers, large and small, across the United States. Now let me update you on Aflac Inc. results. Overall, we're pleased with Aflac's financial performance. Operating earnings per diluted share rose 15.6% to $1.56 for the quarter, or 15.6% or $3.19 for the first 6 months. Excluding the benefit of the stronger yen, operating earnings per diluted share rose 7.4% for the quarter and 8% for the first 6 months. Consistent with the company's previous stated proactive investment de-risking objectives, net earnings in the second quarter included pretax realized investment losses of $668 million, or $453 million after-tax, which is $0.96 per diluted share. During the second quarter of 2011, we sold investment securities with an amortized cost of $1.5 billion, resulting in a realized pretax loss of $182 million. The most notable sales in the quarter included several transactions that lowered our exposure to Peripheral Eurozone Holdings (sic) [Securities]. In addition, the company impaired certain securities resulting in a pretax loss of $528 million. These impairments included exposures to 2 Portuguese banks. As a result of our proactive investment de-risking program, Aflac has significantly reduced Peripheral Eurozone, Perpetual and Financial exposures on an amortized cost basis. As the world stands today, we believe we have substantially completed our proactive investment de-risking program from a realized investment loss perspective and we are comfortable with the current holdings in our below investment grade securities. Our unrealized loss position and below investment grades was $470 million at the end of the second quarter out of $93 billion in investment portfolio. The last time our unrealized loss position in this category was that low, was 2008 pre-financial crisis. Let me tell you that if we thought there was a question with the remaining below investment grade holdings, this would have been the quarter to have taken the action by either selling or impairing them. The strength of our capital position has allowed us to pursue our proactive investment de-risking program to further strengthen our balance sheet and enhance shareholder value for the long term. As we have communicated over the past several years, maintaining a strong risk-based capital or RBC ratio remains a top priority for us. Although we've not yet completed our statutory financial statements for the second quarter, we estimate our RBC ratio will be within the range of 480% to 520% at the end of June. Additionally, we estimate that the solvency margin ratio will be between 520% to 535%, based on the revised calculation methods for the quarter ending June 30, 2011. In Japan, even with significant proactive investment de-risking program in the second quarter, our preliminary solvency margin ratio calculation shows a slight improvement over the solvency margin of 512% for the quarter ending March 31, 2011. We are comfortable with this level, and absent a significant change in the market such as a sudden spike in interest rates, we anticipate it will improve. We also believe these ratios, our overall financial condition prove solid support to our single A credit rating. As you'll recall, 2010 marked the 28th consecutive year of a dividend increase. Our objective remains to increase the cash dividend, generally in line with the earnings growth before the impact of the yen. The board will again evaluate the dividend increase later this year, but I am confident we will extend our consecutive annual dividend increases to 29 years. Additionally, you'll recall that we resumed our share repurchase program in the fourth quarter of 2010. We purchased 1 million shares in the second quarter, bringing in the total number of shares purchased for the 6 months to 4.1 million shares. We anticipate ending up at the low end of the 6 million to 12 million shares repurchase target in 2011. Despite the challenges of the low interest rate environment especially in Japan, we now have 2 good quarters under our belt. Additionally, we believe we've substantially completed our proactive investment de-risking program from a realized investment loss perspective. From an operational standpoint, I think we've done a very good job in managing our expenses. But keep in mind, as the year progresses, we anticipate increasing our spending, particularly on marketing and IT initiatives. Taking all those factors into consideration, I want to reaffirm our 2011 objective of growing operating earnings per diluted share at 8%, excluding the impact of the yen. Looking ahead with this clarity and the year half completed, we expect 2012 earnings per diluted share to increase 2% to 5% on a currency neutral basis. This upward revision to our 2012 earning objective assumes no additional significant investment losses and no meaningful decline in interest rates. Furthermore, once the effects of the proactive investment de-risking program and low investment rates have fully integrated into the financial results, we would expect the range of earnings growth in the future years to improve. I'm pleased with Aflac's overall results for the quarter and for the 6 months. And I can tell you the global financial challenges we've all seen, especially in the changes in the investment environment, have only served to re-energize my enthusiasm as the CEO of this company. And I wouldn't trade places with any other CEO in the world. And now, let me turn the program back to Robin. Robin?